|
US8217149B2
(en)
|
2008-12-09 |
2012-07-10 |
Genentech, Inc. |
Anti-PD-L1 antibodies, compositions and articles of manufacture
|
|
ES2671748T3
(en)
|
2011-07-21 |
2018-06-08 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
|
RU2666730C2
(en)
|
2012-12-07 |
2018-09-12 |
Кемосентрикс, Инк. |
Diazole lactams
|
|
AR095196A1
(en)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
SERUM FREE CELL CULTIVATION MEDIA
|
|
AR097584A1
(en)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1
|
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
PT3049441T
(en)
|
2013-09-27 |
2020-01-21 |
Hoffmann La Roche |
Anti-pdl1 antibody formulations
|
|
TWI681969B
(en)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
Human antibodies to pd-1
|
|
TWI680138B
(en)
*
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
Human antibodies to pd-l1
|
|
JOP20200094A1
(en)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
Antibody Molecules of PD-1 and Their Uses
|
|
JOP20200096A1
(en)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
Antibody molecules to tim-3 and uses thereof
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
CA2936962C
(en)
|
2014-03-14 |
2024-03-05 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
WO2016030455A1
(en)
*
|
2014-08-28 |
2016-03-03 |
Medimmune Limited |
Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
|
|
CA2960824A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of alk inhibitors
|
|
CA2964367C
(en)
|
2014-10-14 |
2024-01-30 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
AU2015360667B2
(en)
|
2014-12-09 |
2021-09-23 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized cluster of differentiation 274 gene
|
|
JP6826055B2
(en)
|
2015-03-13 |
2021-02-03 |
サイトメックス セラピューティクス インコーポレイテッド |
Anti-PDL1 antibody, activating anti-PDL1 antibody, and how to use it
|
|
RU2752729C2
(en)
|
2015-05-18 |
2021-07-30 |
Сумитомо Даиниппон Фарма Онколоджи, Инк. |
Prodrugs of alvocidib having high bioavailability
|
|
PT3297438T
(en)
|
2015-05-21 |
2022-01-25 |
Chemocentryx Inc |
Ccr2 modulators
|
|
US10144779B2
(en)
|
2015-05-29 |
2018-12-04 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
|
TW202440903A
(en)
|
2015-08-04 |
2024-10-16 |
美商再生元醫藥公司 |
Taurine supplemented cell culture medium and methods of use
|
|
DK3353212T3
(en)
|
2015-09-23 |
2021-12-20 |
Regeneron Pharma |
Optimized bispecific anti-CD3 antibodies and uses thereof
|
|
WO2017070110A1
(en)
|
2015-10-19 |
2017-04-27 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
|
BR112018008891A8
(en)
|
2015-11-03 |
2019-02-26 |
Janssen Biotech Inc |
antibodies that specifically bind to pd-1 and tim-3 and their uses
|
|
BR112018012801B1
(en)
|
2015-12-22 |
2024-03-12 |
Regeneron Pharmaceuticals, Inc |
USES OF A COMBINATION OF ANTI-PD-1 ANTIBODIES AND ANTI-CD20/ANTI-CD3 BIESPECIFIC ANTIBODIES AND OF A PHARMACEUTICAL COMPOSITION
|
|
CN106939047B
(en)
|
2016-01-04 |
2021-08-31 |
江苏怀瑜药业有限公司 |
PD-L1 antibody and preparation method thereof
|
|
WO2017125815A2
(en)
*
|
2016-01-22 |
2017-07-27 |
MabQuest SA |
Immunological reagents
|
|
BR112018067698A2
(en)
*
|
2016-02-25 |
2019-01-08 |
Cell Medica Switzerland Ag |
modified cells for immunotherapy
|
|
TWI805127B
(en)
|
2016-03-04 |
2023-06-11 |
美商Ｊｎ生物科學有限責任公司 |
Antibodies to tigit
|
|
HK1247214B
(en)
*
|
2016-03-04 |
2019-07-19 |
四川科伦博泰生物医药股份有限公司 |
Pdl-1 antibody, pharmaceutical composition thereof, and uses thereof
|
|
WO2017156349A1
(en)
|
2016-03-10 |
2017-09-14 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
|
EP3430054B1
(en)
*
|
2016-03-15 |
2021-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
BR112018070361A2
(en)
|
2016-04-07 |
2019-01-29 |
Chemocentryx Inc |
reduction of tumor burden by administration of ccr1 antagonists in combination with pd-1 inhibitors or pd-11 inhibitors
|
|
SG11201809336QA
(en)
*
|
2016-05-09 |
2018-11-29 |
Igm Biosciences Inc |
Anti-pd-l1 antibodies
|
|
TWI786044B
(en)
|
2016-05-13 |
2022-12-11 |
美商再生元醫藥公司 |
Methods of treating skin cancer by administering a pd-1 inhibitor
|
|
KR20230091191A
(en)
|
2016-05-27 |
2023-06-22 |
아게누스 인코포레이티드 |
Anti-tim-3 antibodies and methods of use thereof
|
|
SG11201811003PA
(en)
*
|
2016-06-13 |
2019-01-30 |
I Mab |
Anti-pd-l1 antibodies and uses thereof
|
|
JP7185530B2
(en)
|
2016-06-13 |
2022-12-07 |
トルク セラピューティクス， インコーポレイテッド |
Methods and compositions for promoting immune cell function
|
|
WO2018029474A2
(en)
|
2016-08-09 |
2018-02-15 |
Kymab Limited |
Anti-icos antibodies
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
WO2017220989A1
(en)
*
|
2016-06-20 |
2017-12-28 |
Kymab Limited |
Anti-pd-l1 and il-2 cytokines
|
|
BR112018076684A2
(en)
*
|
2016-06-29 |
2019-04-02 |
Checkpoint Therapeutics, Inc |
specific pd-l1 antibodies and methods of use
|
|
MA45595A
(en)
*
|
2016-07-07 |
2019-05-15 |
Iovance Biotherapeutics Inc |
PROGRAMMED DEATH LIGAND (1) BINDING PROTEINS (1) (PD-L1) AND THEIR METHODS OF USE
|
|
ES2899036T3
(en)
*
|
2016-08-04 |
2022-03-09 |
Innovent Biologics Suzhou Co Ltd |
Anti-PD-L1 nanobody and its use
|
|
KR20230044038A
(en)
|
2016-08-09 |
2023-03-31 |
키맵 리미티드 |
Anti-icos antibodies
|
|
EP3504328A1
(en)
|
2016-08-24 |
2019-07-03 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
WO2018036852A1
(en)
|
2016-08-25 |
2018-03-01 |
F. Hoffmann-La Roche Ag |
Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
|
|
BR112019007369A2
(en)
|
2016-10-11 |
2019-07-16 |
Agenus Inc |
anti-lag-3 antibodies and methods of use
|
|
CN110392694B
(en)
|
2016-11-02 |
2023-08-04 |
震动疗法股份有限公司 |
Antibodies against PD-1 and uses thereof
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
CN110234661B
(en)
*
|
2016-12-01 |
2024-03-29 |
瑞泽恩制药公司 |
Radiolabeled anti-PD-L1 antibodies for use in immunoPET imaging
|
|
MA50949B1
(en)
|
2016-12-07 |
2023-12-29 |
Memorial Sloan Kettering Cancer Center |
ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF
|
|
CA3046082A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
EP3552126B1
(en)
|
2016-12-09 |
2025-05-14 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for sequencing t cell receptors and uses thereof
|
|
RU2759952C2
(en)
|
2016-12-14 |
2021-11-19 |
Янссен Байотек, Инк. |
Cd8a-binding domains of iii fibronectin type
|
|
EP3554561B1
(en)
|
2016-12-14 |
2023-06-28 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
|
EP3554535A4
(en)
|
2016-12-14 |
2020-10-21 |
Janssen Biotech, Inc. |
Pd-l1 binding fibronectin type iii domains
|
|
CN108204958A
(en)
*
|
2016-12-19 |
2018-06-26 |
伊缪泰普有限公司 |
binding assay
|
|
EP3558360A1
(en)
*
|
2016-12-22 |
2019-10-30 |
F. Hoffmann-La Roche AG |
Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
|
|
CN108264561B
(en)
*
|
2016-12-30 |
2021-09-10 |
惠和生物技术(上海)有限公司 |
Tri-functional molecule combining CD19, CD3 and T cell negative co-stimulatory molecule and application thereof
|
|
AU2018207172B2
(en)
|
2017-01-13 |
2023-10-12 |
Mink Therapeutics, Inc. |
T cell receptors that bind to NY-ESO-1 and methods of use thereof
|
|
JP7105238B2
(en)
*
|
2017-01-18 |
2022-07-22 |
ジェネンテック， インコーポレイテッド |
Idiotypic antibodies against anti-PD-L1 antibodies and their uses
|
|
IL268667B2
(en)
|
2017-02-10 |
2024-12-01 |
Regeneron Pharma |
Radiolabeled anti-lag3 antibodies for immuno-pet imaging
|
|
WO2018150224A1
(en)
*
|
2017-02-16 |
2018-08-23 |
Shenzhen Runshin Bioscience |
Anti-programmed death-ligand 1 (pd-l1) antibodies and therapeutic uses thereof
|
|
MX2019009772A
(en)
|
2017-02-21 |
2019-12-02 |
Regeneron Pharma |
Anti-pd-1 antibodies for treatment of lung cancer.
|
|
BR112019017628A2
(en)
|
2017-02-24 |
2020-07-07 |
Macrogenics, Inc. |
cd137 x ta binding molecule, pharmaceutical compositions, use of cd137 x ta binding molecule, cd137 binding molecule, use of cd137 binding molecule, her2 / neu binding molecule, use of her2 binding molecule / neu, and use of a composition
|
|
EP3366703B1
(en)
*
|
2017-02-28 |
2019-04-03 |
Ralf Kleef |
Immune checkpoint therapy with hyperthermia
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
KR102629972B1
(en)
|
2017-04-13 |
2024-01-29 |
아게누스 인코포레이티드 |
Anti-CD137 antibody and methods of using the same
|
|
RU2665790C1
(en)
|
2017-04-17 |
2018-09-04 |
Закрытое Акционерное Общество "Биокад" |
Monoclonal pd-l1 antibody
|
|
AR111651A1
(en)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
|
|
EP3618863B1
(en)
|
2017-05-01 |
2023-07-26 |
Agenus Inc. |
Anti-tigit antibodies and methods of use thereof
|
|
BR112019025188A2
(en)
|
2017-06-01 |
2020-06-23 |
Cytomx Therapeutics, Inc. |
ACTIVABLE ANTI-PDL1 ANTIBODIES AND METHODS OF USE OF THE SAME
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
MY204117A
(en)
|
2017-06-22 |
2024-08-08 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
TW201904993A
(en)
|
2017-06-22 |
2019-02-01 |
瑞士商諾華公司 |
Use of IL-1β binding antibody
|
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
|
|
CN116535508A
(en)
*
|
2017-06-25 |
2023-08-04 |
西雅图免疫公司 |
anti-PD-L1 antibodies and methods of making and using the same
|
|
MX2019015738A
(en)
|
2017-06-27 |
2020-02-20 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof.
|
|
AU2018298039B2
(en)
|
2017-07-06 |
2023-02-02 |
Regeneron Pharmaceuticals, Inc. |
Cell culture process for making a glycoprotein
|
|
EA202090003A1
(en)
*
|
2017-07-06 |
2020-06-18 |
Мерус Н.В. |
BINDING MOLECULES MODULATING THE BIOLOGICAL ACTIVITY THAT A CELL MANIFESTATES
|
|
AU2018302283B2
(en)
|
2017-07-20 |
2025-07-10 |
Novartis Ag |
Dosage regimens of anti-LAG-3 antibodies and uses thereof
|
|
WO2019023148A1
(en)
*
|
2017-07-24 |
2019-01-31 |
Regeneron Pharmaceuticals, Inc. |
Anti-cd8 antibodies and uses thereof
|
|
TWI799432B
(en)
*
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
Anti-ctla-4 antibodies and uses thereof
|
|
CN119019564A
(en)
|
2017-08-01 |
2024-11-26 |
Ab工作室有限公司 |
Bispecific antibodies and their uses
|
|
CA3073055A1
(en)
|
2017-09-04 |
2019-03-07 |
Agenus Inc. |
T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
|
|
JP7196160B2
(en)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
Treatment Regimens for Cancers Insensitive to BCL-2 Inhibitors Using the MCL-1 Inhibitor Albocidib
|
|
US20200216542A1
(en)
*
|
2017-09-20 |
2020-07-09 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
|
|
EP3684955A1
(en)
*
|
2017-09-20 |
2020-07-29 |
Regeneron Pharmaceuticals, Inc. |
Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden
|
|
IL273188B2
(en)
|
2017-09-25 |
2023-03-01 |
Chemocentryx Inc |
Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
|
|
MA50353A
(en)
|
2017-10-10 |
2020-08-19 |
Numab Therapeutics AG |
TARGETING ANTIBODIES PDL1 AND ASSOCIATED METHODS OF USE
|
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
CA3077664A1
(en)
|
2017-11-06 |
2019-05-09 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
AU2018375738A1
(en)
|
2017-11-30 |
2020-06-11 |
Novartis Ag |
BCMA-targeting chimeric antigen receptor, and uses thereof
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
WO2019122882A1
(en)
|
2017-12-19 |
2019-06-27 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
SG11202004380QA
(en)
|
2017-12-22 |
2020-06-29 |
Regeneron Pharma |
System and method for characterizing drug product impurities
|
|
CN115925943A
(en)
*
|
2017-12-27 |
2023-04-07 |
信达生物制药(苏州)有限公司 |
Anti-PD-L1 antibodies and uses thereof
|
|
CN109970856B
(en)
|
2017-12-27 |
2022-08-23 |
信达生物制药(苏州)有限公司 |
anti-LAG-3 antibodies and uses thereof
|
|
JP7383617B2
(en)
|
2017-12-28 |
2023-11-20 |
ナンジン レジェンド バイオテック カンパニー，リミテッド |
Antibodies against PD-L1 and variants thereof
|
|
WO2019136210A1
(en)
*
|
2018-01-04 |
2019-07-11 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
MA50423A
(en)
|
2018-01-08 |
2020-08-26 |
Chemocentryx Inc |
SOLID TUMOR TREATMENT METHODS USING CCR2 ANTAGONISTS
|
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
US20190269664A1
(en)
|
2018-01-08 |
2019-09-05 |
Chemocentryx, Inc. |
Methods of treating solid tumors with ccr2 antagonists
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
|
CN111655722A
(en)
|
2018-01-31 |
2020-09-11 |
瑞泽恩制药公司 |
Systems and Methods for Characterizing Drug Product Impurities
|
|
TW202311746A
(en)
|
2018-02-02 |
2023-03-16 |
美商再生元醫藥公司 |
System and method for characterizing protein dimerization
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
GB201802573D0
(en)
*
|
2018-02-16 |
2018-04-04 |
Crescendo Biologics Ltd |
Therapeutic molecules that bind to LAG3
|
|
BR112020013426A2
(en)
|
2018-02-28 |
2020-12-01 |
Regeneron Pharmaceuticals, Inc. |
methods for identifying a virus in a sample and for detecting viral nucleic acids in a cell culture sample
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
EA202092203A1
(en)
|
2018-03-19 |
2020-12-07 |
Ридженерон Фармасьютикалз, Инк. |
METHODS OF ANALYSIS AND REAGENTS FOR MICROCHIP CAPILLARY ELECTROPHORESIS
|
|
US20210017284A1
(en)
*
|
2018-03-19 |
2021-01-21 |
Abeome Corporation |
High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof
|
|
JP7680208B2
(en)
|
2018-04-04 |
2025-05-20 |
ブリストル－マイヤーズ スクイブ カンパニー |
Anti-CD27 Antibodies and Uses Thereof
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
CN117568287A
(en)
*
|
2018-04-15 |
2024-02-20 |
深圳市亦诺微医药科技有限公司 |
Antibodies that bind PD-1 and their uses
|
|
AU2019256383A1
(en)
|
2018-04-17 |
2020-11-26 |
Celldex Therapeutics, Inc. |
Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
|
|
EP3784688A2
(en)
|
2018-04-26 |
2021-03-03 |
Agenus Inc. |
Heat shock protein-binding peptide compositions and methods of use thereof
|
|
TW202016125A
(en)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
Systems and methods for quantifying and modifying protein viscosity
|
|
US11866499B2
(en)
*
|
2018-05-24 |
2024-01-09 |
Janssen Biotech, Inc. |
Monospecific and multispecific anti-TMEFF2 antibodies and their uses
|
|
TWI869346B
(en)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
US12331068B2
(en)
|
2018-05-31 |
2025-06-17 |
Peloton Therapeutics, Inc. |
Compositions and methods for inhibiting CD73
|
|
CN118459594A
(en)
|
2018-06-01 |
2024-08-09 |
诺华股份有限公司 |
Binding molecules to BCMA and uses thereof
|
|
AU2019288728A1
(en)
|
2018-06-23 |
2021-01-14 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
|
AR116109A1
(en)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
|
|
DK3820573T3
(en)
|
2018-07-10 |
2023-10-23 |
Novartis Ag |
3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES
|
|
TWI822815B
(en)
*
|
2018-07-14 |
2023-11-21 |
財團法人生物技術開發中心 |
Anti- human pd-l1 antibodies and their uses
|
|
TW202011991A
(en)
|
2018-07-18 |
2020-04-01 |
美商建南德克公司 |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
|
WO2020020307A1
(en)
|
2018-07-25 |
2020-01-30 |
I-Mab Biopharma Co., Ltd. |
Anti-cd73 anti-pd-l1 bispecific antibodies
|
|
EA202092684A1
(en)
|
2018-08-27 |
2021-03-11 |
Ридженерон Фармасьютикалз, Инк. |
APPLICATION OF RAMAN SPECTROSCOPY FOR FOLLOWING CLEANING
|
|
TWI866924B
(en)
|
2018-08-30 |
2024-12-21 |
美商再生元醫藥公司 |
Methods for characterizing protein complexes
|
|
TW202024023A
(en)
|
2018-09-03 |
2020-07-01 |
瑞士商赫孚孟拉羅股份公司 |
Therapeutic compounds and methods of use
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
CN112638950B
(en)
*
|
2018-10-22 |
2024-09-06 |
南通壹宸生物医药科技有限公司 |
A bispecific antibody
|
|
EP3873500A4
(en)
|
2018-10-31 |
2023-01-11 |
Mayo Foundation for Medical Education and Research |
CANCER TREATMENT METHODS AND MATERIALS
|
|
WO2020089811A1
(en)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
EP3873540A4
(en)
|
2018-10-31 |
2022-07-27 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
|
|
HUE067601T2
(en)
|
2018-11-14 |
2024-10-28 |
Regeneron Pharma |
Intralesional administration of pd-1 inhibitors for treating skin cancer
|
|
CN113490499A
(en)
|
2018-12-04 |
2021-10-08 |
大日本住友制药肿瘤公司 |
CDK9 inhibitors and polymorphs thereof as active agents for the treatment of cancer
|
|
BR112021011224A2
(en)
|
2018-12-11 |
2021-08-24 |
Theravance Biopharma R&D Ip, Llc |
alk5 inhibitors
|
|
KR20210106437A
(en)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
Dosage regimens and pharmaceutical combinations comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
KR20210108422A
(en)
|
2018-12-21 |
2021-09-02 |
노파르티스 아게 |
Uses of IL-1β Binding Antibodies
|
|
MX2021007271A
(en)
|
2018-12-21 |
2021-07-15 |
Onxeo |
New conjugated nucleic acid molecules and their uses.
|
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
|
US20220025036A1
(en)
|
2018-12-21 |
2022-01-27 |
Novartis Ag |
Use of il-1beta binding antibodies
|
|
US20200369762A1
(en)
|
2018-12-21 |
2020-11-26 |
Novartis Ag |
Use of il-1beta binding antibodies
|
|
AU2019413690A1
(en)
*
|
2018-12-27 |
2021-08-12 |
Gigagen, Inc. |
Anti-PD-L1 binding proteins and methods of use thereof
|
|
CN111378044B
(en)
*
|
2018-12-28 |
2022-07-15 |
长春金赛药业有限责任公司 |
Antibody fusion protein, preparation method and application thereof
|
|
JP2022518399A
(en)
|
2019-01-14 |
2022-03-15 |
ジェネンテック， インコーポレイテッド |
How to Treat Cancer with PD-1 Axial Binding Antagonists and RNA Vaccines
|
|
CN117110492A
(en)
|
2019-01-16 |
2023-11-24 |
瑞泽恩制药公司 |
Methods to identify free sulfhydryl groups in proteins
|
|
TWI756621B
(en)
*
|
2019-01-25 |
2022-03-01 |
大陸商信達生物製藥（蘇州）有限公司 |
Novel bispecific antibody molecules and bispecific antibodies that simultaneously bind pd-l1 and lag-3
|
|
CN113660956B
(en)
|
2019-01-28 |
2024-10-29 |
Ab诊疗公司 |
Bispecific antibodies and their uses
|
|
CA3127502A1
(en)
|
2019-02-12 |
2020-08-20 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
US12479817B2
(en)
|
2019-02-15 |
2025-11-25 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
AU2020222345B2
(en)
|
2019-02-15 |
2022-11-17 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
MA55084A
(en)
|
2019-02-28 |
2022-01-05 |
Regeneron Pharma |
ADMINISTRATION OF PD-1 INHIBITORS FOR THE TREATMENT OF SKIN CANCER
|
|
WO2020180727A1
(en)
|
2019-03-06 |
2020-09-10 |
Regeneron Pharmaceuticals, Inc. |
Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
|
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
|
JP7547360B2
(en)
|
2019-03-22 |
2024-09-09 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
Compositions Comprising PKM2 Modulators and Methods of Treatment Using Same
|
|
CN109929037B
(en)
*
|
2019-04-01 |
2023-03-17 |
华博生物医药技术（上海）有限公司 |
Conjugates to programmed death ligands and uses thereof
|
|
JP7725066B2
(en)
*
|
2019-04-18 |
2025-08-19 |
キューエルエスエフ バイオセラピューティック インコーポレイテッド |
Humanized anti-PD-L1 antibody
|
|
BR112021020867A2
(en)
|
2019-04-19 |
2022-01-04 |
Genentech Inc |
Antibodies, nucleic acid, vector, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, uses of the antibody, method of treating an individual with cancer, and method of reducing clearance
|
|
WO2020216379A1
(en)
*
|
2019-04-26 |
2020-10-29 |
I-Mab |
Human pd-l1 antibodies
|
|
SG11202110911RA
(en)
|
2019-05-13 |
2021-10-28 |
Regeneron Pharma |
Improved competitive ligand binding assays
|
|
JP7489407B2
(en)
|
2019-05-21 |
2024-05-23 |
ノバルティス アーゲー |
CD19 binding molecules and uses thereof
|
|
CN111606995B
(en)
*
|
2019-06-04 |
2021-02-12 |
优睿赛思(武汉)生物科技有限公司 |
Anti-human PD-L1 monoclonal antibody and application thereof
|
|
US20220220204A1
(en)
*
|
2019-06-12 |
2022-07-14 |
Nanjing GenScript Biotech Co., Ltd. |
Anti-pd-l1/anti-lag-3 multiple antigen binding proteins and methods of use thereof
|
|
KR20220024594A
(en)
|
2019-06-21 |
2022-03-03 |
리제너론 파마슈티칼스 인코포레이티드 |
Combination of 4-1BB co-stimulation with dual specific antigen binding molecules that bind PSMA and CD3
|
|
US12091460B2
(en)
|
2019-06-21 |
2024-09-17 |
Regeneron Pharmaceuticals, Inc. |
Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation
|
|
EP3994132A1
(en)
|
2019-07-03 |
2022-05-11 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
|
|
GB201910138D0
(en)
*
|
2019-07-15 |
2019-08-28 |
Capella Bioscience Ltd |
Anti-pd-l1 antibodies
|
|
CN110305906B
(en)
*
|
2019-07-18 |
2021-11-12 |
山东大学第二医院 |
PDL 1-targeted lentiviral vector of CAR chimeric receptor and PDL1-CAR-T cell
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
CN112409484B
(en)
*
|
2019-08-22 |
2023-03-21 |
盛禾(中国)生物制药有限公司 |
Multifunctional antibodies, their preparation and uses
|
|
BR112021016512A2
(en)
*
|
2019-08-29 |
2022-03-15 |
Remegen Co Ltd |
Anti pd-l1 antibody and its use
|
|
US11680098B2
(en)
|
2019-08-30 |
2023-06-20 |
Agenus Inc. |
Antibodies that specifically bind human CD96
|
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
TW202124446A
(en)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
Combination therapies with entpd2 antibodies
|
|
BR112022004885A2
(en)
|
2019-09-24 |
2022-06-07 |
Regeneron Pharma |
Systems and methods for use and regeneration of chromatography
|
|
KR20220071264A
(en)
*
|
2019-09-30 |
2022-05-31 |
하버 바이오메드 (상하이) 컴퍼니 리미티드 |
Anti-PD-L1 antigen binding protein and applications thereof
|
|
US12491255B2
(en)
|
2019-10-14 |
2025-12-09 |
Aro Biotherapeutics Company |
EPCAM binding fibronectin type III domains
|
|
US11628222B2
(en)
|
2019-10-14 |
2023-04-18 |
Aro Biotherapeutics Company |
CD71 binding fibronectin type III domains
|
|
US11781138B2
(en)
|
2019-10-14 |
2023-10-10 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
|
KR20220103947A
(en)
|
2019-10-21 |
2022-07-25 |
노파르티스 아게 |
Combination Therapy with Venetoclax and TIM-3 Inhibitors
|
|
CN114786680A
(en)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
TIM-3 inhibitors and uses thereof
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
WO2021091964A1
(en)
|
2019-11-04 |
2021-05-14 |
Duke University |
Treatment for primary and metastatic cancer
|
|
WO2021088904A1
(en)
*
|
2019-11-08 |
2021-05-14 |
先声生物医药科技有限公司 |
Anti-human programmed cell death ligand-1 (pd-l1) antibody and use thereof
|
|
CN112858678B
(en)
*
|
2019-11-12 |
2023-10-27 |
上海奥普生物医药股份有限公司 |
Creatine kinase isoenzyme detection kit, preparation method and application
|
|
WO2021097110A1
(en)
|
2019-11-13 |
2021-05-20 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
WO2021102343A1
(en)
|
2019-11-22 |
2021-05-27 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Solid dose pharmaceutical composition
|
|
JP2023502662A
(en)
|
2019-11-22 |
2023-01-25 |
セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー |
Substituted 1,5-naphthyridines or quinolines as ALK5 inhibitors
|
|
IL293112A
(en)
|
2019-11-25 |
2022-07-01 |
Regeneron Pharma |
Sustained release formulations using non-aqueous emulsions
|
|
EP4069746A4
(en)
*
|
2019-12-04 |
2023-12-27 |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd. |
BISPECIFIC FUSION PROTEIN FOR THE TREATMENT OF TUMORS
|
|
JP2023506958A
(en)
|
2019-12-20 |
2023-02-20 |
ノバルティス アーゲー |
Combination of the anti-TIM-3 antibody MBG453 and the anti-TGF-beta antibody NIS793 with or without decitabine or the anti-PD-1 antibody spartalizumab for treating myelofibrosis and myelodysplastic syndrome
|
|
IL293752A
(en)
|
2020-01-17 |
2022-08-01 |
Novartis Ag |
A combination containing a tim-3 inhibitor and a substance that causes hypomethylation for use in the treatment of myeloplastic syndrome or chronic myelomonocytic leukemia
|
|
BR112022014212B1
(en)
|
2020-01-21 |
2024-01-23 |
Regeneron Pharmaceuticals, Inc |
METHODS FOR ANALYSIS OF A SAMPLE INCLUDING A PROTEIN OF INTEREST
|
|
KR20210095781A
(en)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
A multi-specific antibody comprising a fusion construct consisting of a Fab and a bioactive effector moiety
|
|
WO2021152005A1
(en)
|
2020-01-28 |
2021-08-05 |
Universite De Strasbourg |
Antisense oligonucleotide targeting linc00518 for treating melanoma
|
|
BR112022015077A2
(en)
|
2020-01-31 |
2022-10-04 |
Genentech Inc |
METHODS TO INDUCE NEOEPITOPE-SPECIFIC CD8+ T CELLS IN AN INDIVIDUAL WITH A TUMOR AND TO INDUCE CD8+ T CELL TRAFFICKING, RNA VACCINES, RNA VACCINE FOR USE AND BINDING ANTAGONISTS
|
|
CN113318226A
(en)
*
|
2020-02-28 |
2021-08-31 |
正大天晴药业集团股份有限公司 |
Method for treating lung cancer by anti-PD-L1 antibody and radioactive rays
|
|
US11673879B2
(en)
|
2020-03-31 |
2023-06-13 |
Theravance Biopharma R&D Ip, Llc |
Substituted pyrimidines and methods of use
|
|
IL298273A
(en)
|
2020-05-26 |
2023-01-01 |
Regeneron Pharma |
Methods for the treatment of cervical cancer using the administration of the pd-1 inhibitory antibody Semilimb
|
|
LT4157876T
(en)
|
2020-05-26 |
2024-10-25 |
Boehringer Ingelheim International Gmbh |
Anti-pd-1 antibodies
|
|
AU2021284273A1
(en)
|
2020-06-02 |
2022-12-15 |
Arcus Biosciences, Inc. |
Antibodies to TIGIT
|
|
US20210387983A1
(en)
|
2020-06-10 |
2021-12-16 |
Theravance Biopharma R&D Ip, Llc |
Crystalline alk5 inhibitors and uses thereof
|
|
TW202214857A
(en)
|
2020-06-19 |
2022-04-16 |
法商昂席歐公司 |
New conjugated nucleic acid molecules and their uses
|
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
CA3182579A1
(en)
|
2020-07-07 |
2022-01-13 |
Ugur Sahin |
Therapeutic rna for hpv-positive cancer
|
|
TW202216778A
(en)
|
2020-07-15 |
2022-05-01 |
美商安進公司 |
Tigit and cd112r blockade
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
WO2022029573A1
(en)
|
2020-08-03 |
2022-02-10 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
AU2021329378A1
(en)
|
2020-08-19 |
2023-03-23 |
Xencor, Inc. |
Anti-CD28 compositions
|
|
CA3168743A1
(en)
|
2020-08-26 |
2022-03-03 |
Matthew G. Fury |
Methods of treating cancer by administering a pd-1 inhibitor
|
|
KR20230058094A
(en)
|
2020-08-31 |
2023-05-02 |
리제너론 파아마슈티컬스, 인크. |
Asparagine supply strategies to improve cell culture performance and mitigate asparagine sequence variants
|
|
WO2022051448A1
(en)
|
2020-09-03 |
2022-03-10 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer pain by administering a pd-1 inhibitor
|
|
AR123855A1
(en)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE
|
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
|
WO2022098638A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
US20220153842A1
(en)
|
2020-11-04 |
2022-05-19 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
|
MX2023005130A
(en)
|
2020-11-04 |
2023-05-25 |
Genentech Inc |
SUBCUTANEOUS DOSE OF ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES.
|
|
US20240025993A1
(en)
|
2020-11-06 |
2024-01-25 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
WO2022095970A1
(en)
*
|
2020-11-06 |
2022-05-12 |
百奥泰生物制药股份有限公司 |
Bispecific antibody and use thereof
|
|
EP4244247A4
(en)
*
|
2020-11-13 |
2024-12-18 |
Sab, Llc |
POLYCLONAL IMMUNOGLOBULIN DERIVED FROM UNGULATES SPECIFIC FOR PD-L1 AND ITS USES
|
|
WO2022115588A1
(en)
|
2020-11-25 |
2022-06-02 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
|
CA3202523A1
(en)
|
2020-12-02 |
2022-06-09 |
Genentech, Inc. |
Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
|
|
TW202237119A
(en)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk-5 inhibitors and uses thereof
|
|
US12350374B2
(en)
|
2020-12-17 |
2025-07-08 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
|
TW202245808A
(en)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
Therapeutic rna for treating cancer
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
CN114656565B
(en)
*
|
2020-12-23 |
2024-04-23 |
广东菲鹏制药股份有限公司 |
Anti-PD-L1 antibody and application thereof
|
|
JP2024503408A
(en)
|
2021-01-20 |
2024-01-25 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
How to improve protein titer in cell culture
|
|
US20240141060A1
(en)
|
2021-01-29 |
2024-05-02 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
JP2024507144A
(en)
|
2021-02-11 |
2024-02-16 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Method of treating cancer by administering a neoadjuvant PD-1 inhibitor
|
|
IL304998A
(en)
|
2021-02-23 |
2023-10-01 |
Regeneron Pharma |
Methods of treating lung cancer by administering a pd-1 inhibitor
|
|
JP2024512299A
(en)
|
2021-03-03 |
2024-03-19 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Systems and methods for quantifying and modifying protein viscosity
|
|
CN117321418A
(en)
|
2021-03-18 |
2023-12-29 |
诺华股份有限公司 |
Cancer biomarkers and how to use them
|
|
AU2022242000A1
(en)
|
2021-03-23 |
2023-09-14 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
|
|
TW202304506A
(en)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
|
US20220309215A1
(en)
|
2021-03-26 |
2022-09-29 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing mixing protocols
|
|
TW202304979A
(en)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
|
|
BR112023021111A2
(en)
|
2021-04-13 |
2023-12-19 |
Nuvalent Inc |
COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OF CANCER, METHOD OF SELECTIVELY INHIBITING HER2, METHOD OF REGULATING A LEVEL OF HER2, METHOD OF INCREASING A LEVEL OF HER2, METHOD OF DECREASING THE PHOSPHORYLATION OF HER2
|
|
CA3214552A1
(en)
|
2021-04-14 |
2022-10-20 |
Russell C. Addis |
Cd71 binding fibronectin type iii domains
|
|
CA3215367A1
(en)
|
2021-04-14 |
2022-10-20 |
Swapnil Kulkarni |
Fn3 domain-sirna conjugates and uses thereof
|
|
EP4330282A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
WO2022232503A1
(en)
|
2021-04-30 |
2022-11-03 |
Genentech, Inc. |
Therapeutic and diagnostic methods and compositions for cancer
|
|
CA3219336A1
(en)
|
2021-05-18 |
2022-11-24 |
Kymab Limited |
Uses of anti-icos antibodies
|
|
AR125874A1
(en)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
COMBINATION THERAPIES
|
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
|
CA3220848A1
(en)
|
2021-06-01 |
2022-12-08 |
Timothy Riehlman |
Microchip capillary electrophoresis assays and reagents
|
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
|
KR20240028452A
(en)
|
2021-07-02 |
2024-03-05 |
제넨테크, 인크. |
Methods and compositions for treating cancer
|
|
JP2024525758A
(en)
|
2021-07-13 |
2024-07-12 |
ビオンテック・ソシエタス・エウロパエア |
Multispecific binding agents to CD40 and CD137 in combination therapy for cancer - Patents.com
|
|
AU2022314735A1
(en)
|
2021-07-19 |
2024-02-22 |
Regeneron Pharmaceuticals, Inc. |
Combination of checkpoint inhibitors and an oncolytic virus for treating cancer
|
|
MX2024001214A
(en)
|
2021-07-28 |
2024-02-12 |
Hoffmann La Roche |
Methods and compositions for treating cancer.
|
|
EP4377350A2
(en)
|
2021-07-28 |
2024-06-05 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
|
US20230077710A1
(en)
|
2021-09-08 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
|
|
CN118139881A
(en)
|
2021-09-20 |
2024-06-04 |
瑞泽恩制药公司 |
Method for controlling antibody heterogeneity
|
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
|
TW202321308A
(en)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
|
TW202323817A
(en)
|
2021-10-07 |
2023-06-16 |
美商再生元醫藥公司 |
Systems and methods of ph modeling and control
|
|
IL311248A
(en)
|
2021-10-07 |
2024-05-01 |
Regeneron Pharma |
Ph meter calibration and correction
|
|
TW202333802A
(en)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
Therapeutic rna for lung cancer
|
|
TW202330104A
(en)
|
2021-10-26 |
2023-08-01 |
美商再生元醫藥公司 |
Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
|
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
|
JP2024541508A
(en)
|
2021-11-24 |
2024-11-08 |
ジェネンテック， インコーポレイテッド |
Therapeutic indazole compounds and methods of use in the treatment of cancer - Patents.com
|
|
US12275745B2
(en)
|
2021-11-24 |
2025-04-15 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
CN118660964A
(en)
|
2021-12-16 |
2024-09-17 |
瓦莱里奥治疗公司 |
Novel conjugated nucleic acid molecules and uses thereof
|
|
IL314851A
(en)
|
2022-02-17 |
2024-10-01 |
Regeneron Pharma |
Combinations of checkpoint inhibitors and oncolytic virus for cancer treatment
|
|
CA3252619A1
(en)
|
2022-02-23 |
2023-08-31 |
Xencor, Inc. |
Anti-cd28 x anti-psma antibodies
|
|
EP4493189A1
(en)
|
2022-03-14 |
2025-01-22 |
Laekna Limited |
Combination treatment for cancer
|
|
EP4493921A1
(en)
|
2022-03-18 |
2025-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for analyzing polypeptide variants
|
|
WO2023187460A1
(en)
*
|
2022-04-01 |
2023-10-05 |
Mabtree Biologics Ag |
Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function
|
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
EP4519326A1
(en)
*
|
2022-05-04 |
2025-03-12 |
Janux Therapeutics, Inc. |
Tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
CA3251472A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
EP4525991A1
(en)
|
2022-05-18 |
2025-03-26 |
Kymab Limited |
Uses of anti-icos antibodies
|
|
KR20250022049A
(en)
|
2022-06-07 |
2025-02-14 |
제넨테크, 인크. |
Method for determining the efficacy of a treatment for lung cancer comprising an anti-PD-L1 antagonist and an anti-TIGIT antagonist antibody
|
|
CN119585308A
(en)
|
2022-07-13 |
2025-03-07 |
基因泰克公司 |
Administration of anti-FCRH5/anti-CD3 bispecific antibodies for treatment
|
|
EP4558524A1
(en)
|
2022-07-19 |
2025-05-28 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
CN120153254A
(en)
|
2022-09-01 |
2025-06-13 |
基因泰克公司 |
Bladder cancer treatment and diagnosis
|
|
WO2024077095A1
(en)
|
2022-10-05 |
2024-04-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating bladder cancer
|
|
EP4599088A1
(en)
|
2022-10-05 |
2025-08-13 |
Genentech, Inc. |
Methods and compositions for classifying and treating lung cancer
|
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
|
CN120302979A
(en)
|
2022-12-01 |
2025-07-11 |
生物技术公司 |
Combination therapy of multispecific antibodies targeting CD40 and CD137 with anti-PD1 Ab and chemotherapy
|
|
WO2024126457A1
(en)
|
2022-12-14 |
2024-06-20 |
Astellas Pharma Europe Bv |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
|
|
EP4634659A1
(en)
|
2022-12-16 |
2025-10-22 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
KR20250122520A
(en)
|
2022-12-20 |
2025-08-13 |
제넨테크, 인크. |
Method for treating pancreatic cancer using a PD-1 axis binding antagonist and an RNA vaccine
|
|
EP4655595A1
(en)
|
2023-01-25 |
2025-12-03 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
WO2024158880A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
EP4658310A1
(en)
|
2023-01-30 |
2025-12-10 |
Kymab Limited |
Antibodies
|
|
WO2024163708A1
(en)
|
2023-02-01 |
2024-08-08 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
|
US20240299601A1
(en)
|
2023-02-17 |
2024-09-12 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-lag3 antibodies for immuno-pet imaging
|
|
US20240280551A1
(en)
|
2023-02-22 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
System suitability parameters and column aging
|
|
WO2024216028A1
(en)
|
2023-04-12 |
2024-10-17 |
Agenus Inc. |
Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
|
|
WO2024218509A1
(en)
*
|
2023-04-19 |
2024-10-24 |
Centessa Pharmaceuticals (Uk) Limited |
Activatable bispecific anti-cd28 and anti pd-l1 proteins and uses thereof
|
|
WO2024223299A2
(en)
|
2023-04-26 |
2024-10-31 |
Isa Pharmaceuticals B.V. |
Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
|
|
AU2024265540A1
(en)
|
2023-05-01 |
2025-10-30 |
Regeneron Pharmaceuticals, Inc. |
Multidose antibody drug products using phenol or benzyl alcohol
|
|
AU2024270495A1
(en)
|
2023-05-05 |
2025-10-09 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
AU2024268933A1
(en)
|
2023-05-10 |
2025-11-20 |
Chugai Seiyaku Kabushiki Kaisha |
Methods and compositions for treating cancer
|
|
WO2024263904A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2024263195A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2025024257A1
(en)
|
2023-07-21 |
2025-01-30 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2025049277A1
(en)
|
2023-08-25 |
2025-03-06 |
Genentech, Inc. |
Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
|
|
TW202528736A
(en)
|
2023-09-08 |
2025-07-16 |
美商再生元醫藥公司 |
Methods and systems for assessing chromatographic column integrity
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
WO2025064403A2
(en)
|
2023-09-18 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing chromatography protocols
|
|
TW202532098A
(en)
|
2023-09-29 |
2025-08-16 |
美商再生元醫藥公司 |
Lyophilization using controlled nucleation
|
|
WO2025080538A1
(en)
|
2023-10-09 |
2025-04-17 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine
|
|
WO2025085404A1
(en)
|
2023-10-16 |
2025-04-24 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treating lung cancer
|
|
WO2025085594A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
TW202535934A
(en)
|
2023-11-02 |
2025-09-16 |
美商再生元醫藥公司 |
Methods for reducing lipase activity using stress
|
|
WO2025117889A2
(en)
|
2023-11-30 |
2025-06-05 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer by administering a combination therapy including a neoadjuvant pd-1 inhibitor
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2025121445A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025155607A1
(en)
|
2024-01-16 |
2025-07-24 |
Genentech, Inc. |
Methods of treating urothelial carcinoma with a pd-1 axis binding antagonist and an rna vaccine
|
|
WO2025166228A1
(en)
*
|
2024-01-31 |
2025-08-07 |
D2M Biotherapeutics Limited |
Anti-il12p35 antibodies and uses thereof
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025174933A1
(en)
|
2024-02-14 |
2025-08-21 |
Genentech, Inc. |
Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
WO2025194043A1
(en)
|
2024-03-15 |
2025-09-18 |
Regeneron Pharmaceuticals, Inc. |
Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
|
|
WO2025259840A1
(en)
|
2024-06-13 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for scaled chromatography
|